The BCL7A Knockout HAP1 Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BCL7A gene in HAP1 cells. This heterogeneous pool, generated through CRISPR/Cas9-mediated gene disruption, provides a powerful loss-of-function model for investigating BCL7A’s role in cellular processes. As polyclonal knockout cells, they represent a population-wide gene inactivation, avoiding clonal bias and facilitating robust functional studies without the need for single-cell isolation.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia line. Its haploid genome simplifies knockout studies because disruption of a single allele yields a complete functional knockout, enabling unambiguous genotype?Cphenotype correlations. This feature makes HAP1 an ideal host for high-throughput genetic screens and targeted gene inactivation in a human context. The parental cells retain key characteristics of myeloid lineages, providing a relevant background for studying hematopoietic disorders.
BCL7A encodes a tumor suppressor and vital subunit of the SWI/SNF ATP?dependent chromatin remodeling complex. Within this complex, BCL7A interacts directly with core catalytic components including SMARCA4 (BRG1), SMARCC1, and SMARCC2, as well as with CTNNB1 (???catenin), linking its activity to WNT signaling. Mechanistically, BCL7A facilitates chromatin remodeling that regulates transcription of genes governing cell cycle progression, apoptosis, and differentiation. WNT/???catenin signaling acts upstream to modulate BCL7A?containing SWI/SNF complexes, thereby influencing expression of downstream targets such as cell cycle regulators and apoptosis?related genes.
In the HAP1 background, disruption of BCL7A creates a powerful model for dissecting its tumor?suppressive functions in a simplified genetic landscape. The near?haploid setting accentuates the phenotypic consequences of BCL7A loss, aiding in clarification of its role in B?cell malignancies, including B?cell chronic lymphocytic leukemia, non?Hodgkin lymphoma, and multiple myeloma, where BCL7A is frequently dysregulated. The polyclonal knockout population mirrors the genetic diversity of tumor environments, improving the translational relevance of findings.
Researchers can employ these BCL7A knockout cells in a broad range of assays. Western blotting and RT?qPCR enable verification of BCL7A ablation and downstream target gene expression changes. Chromatin immunoprecipitation (ChIP?qPCR) reveals altered SWI/SNF occupancy at specific genomic loci. Functional outcomes such as proliferation, viability, and apoptosis can be assessed using standard cellular assays and flow cytometry. Co?immunoprecipitation experiments with interaction partners like CTNNB1 and SMARCA4 help map protein interaction networks. This polyclonal knockout model is thus suited for functional genomics, drug target validation, and mechanistic studies of chromatin remodeling in cancer. For further technical information, please contact Ascent Research.
